KNACKMUSS; Stefan

Patent Applications and Registrations

Patent applications and USPTO patent grants for KNACKMUSS; Stefan.The latest application filed is for "tandem diabody for cd16a-directed nk-cell engagement".

Company Profile

4.17.16

KNACKMUSS; Stefan - Planckstadt DE
Knackmuss; Stefan - Plankstadt DE

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Tandem Diabody for CD16A-directed NK-cell Engagement App 20220041717 - ROSS; Thorsten ; et al.	2022-02-10
Tandem diabody for CD16A-directed NK-cell engagement Grant 11,180,558 - Ross , et al. November 23, 2	2021-11-23
Combination of a CD30XCD16 antibody with a PD-1 antagonist for therapy Grant 11,167,029 - Treder , et al. November 9, 2	2021-11-09
Bispecific CD33 and CD3 Binding Proteins App 20210024654 - Ellwanger; Kristina ; et al.	2021-01-28
Bispecific CD33 and CD3 binding proteins Grant 10,626,190 - Ellwanger , et al.	2020-04-21
Tandem Diabody for CD16A-directed NK-cell Engagement App 20190345249 - Ross; Thorsten ; et al.	2019-11-14
Antibody binding sites specific for EGFRvIII Grant 10,273,309 - Ellwanger , et al.	2019-04-30
Bispecific CD33 and CD3 Binding Proteins App 20180291113 - ELLWANGER; Kristina ; et al.	2018-10-11
CD3 binding domains Grant 10,066,015 - Zhukovsky , et al. September 4, 2	2018-09-04
Combination Of A Cd30xcd16 Antibody With A Pd-1 Antagonist For Therapy App 20180085456 - TREDER; Martin ; et al.	2018-03-29
Bispecific CD33 and CD3 binding proteins Grant 9,803,029 - Ellwanger , et al. October 31, 2	2017-10-31
Anti-CD16 binding molecules Grant 9,701,750 - Hoffmann , et al. July 11, 2	2017-07-11
Compounds For Use In The Treatment Of Alzheimer's Disease App 20160361413 - Weiss; Stefan Franz Thomas ; et al.	2016-12-15
Bispecific CD33 and CD3 Binding Proteins App 20160194409 - ELLWANGER; Kristina ; et al.	2016-07-07
Compounds for use in the treatment of Alzheimer's disease Grant 9,365,647 - Weiss , et al. June 14, 2	2016-06-14
ANTIBODY BINDING SITES SPECIFIC FOR EGFRvIII App 20160152728 - ELLWANGER; Kristina ; et al.	2016-06-02
Cd3 Binding Domains App 20160039934 - ZHUKOVSKY; Eugene ; et al.	2016-02-11
Bispecific CD33 and CD3 Binding Proteins App 20160002333 - ELLWANGER; Kristina ; et al.	2016-01-07
Bispecific CD33 and CD3 binding proteins Grant 9,212,225 - Ellwanger , et al. December 15, 2	2015-12-15
Anti-cd16 Binding Molecules App 20150218275 - Hoffmann; Karin ; et al.	2015-08-06
Anti-CD16 binding molecules Grant 9,035,026 - Hoffmann , et al. May 19, 2	2015-05-19
Compounds For Use In The Treatment Of Alzheimer's Disease App 20140220041 - Weiss; Stefan Franz Thomas ; et al.	2014-08-07
Human antibody specific for activated state of platelet integrin receptor GPIIb/IIIa Grant 8,455,627 - Linhard , et al. June 4, 2	2013-06-04
Antibody Of Human Origin For Inhibiting Thrombocytes Aggregation App 20110165175 - Linhard; Claudia ; et al.	2011-07-07
Use of an antibody against the laminin receptor or laminin receptor precursor for the treatment or diagnosis of several cancer types Grant 7,901,677 - Little , et al. March 8, 2	2011-03-08
Antibody of human origin specifically binding to activated state of platelet integrin receptor GPIIb/IIIa Grant 7,812,136 - Buettner , et al. October 12, 2	2010-10-12
Anti-cd16 binding molecules App 20090214574 - Hoffmann; Karin ; et al.	2009-08-27
Single-chain antibody acting against 37 kDa/67 kDa Iaminin receptor as tools for the diagnosis and therapy of prion diseases and cancer, production and use thereof Grant 7,507,797 - Knackmuss , et al. March 24, 2	2009-03-24
Single-chain antibody acting against 37 kda/67 kda laminin receptor as tools for the diagnosis and therapy of prion diseases and cancer, production and use thereof App 20070041977 - Knackmuss; Stefan ; et al.	2007-02-22

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.